Obesity Pipeline Review, H1 2017 - Therapeutics Report on 96 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Obesity - Pipeline Review, H1 2017" report to their offering.

Obesity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 16, 22, 129, 30 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 50 and 14 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Obesity - Overview
  3. Obesity - Therapeutics Development
  4. Obesity - Therapeutics Assessment
  5. Obesity - Companies Involved in Therapeutics Development
  6. Obesity - Drug Profiles
  7. Obesity - Dormant Projects
  8. Obesity - Discontinued Products
  9. Obesity - Product Development Milestones
  10. Appendix

Companies Mentioned

  • Abeome Corp
  • Amabiotics SAS
  • Amgen Inc
  • Evotec AG
  • F. Hoffmann-La Roche Ltd
  • FibroGen Inc
  • Genmedica Therapeutics SL
  • Gila Therapeutics Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • GTx Inc
  • Lead Discovery Center GmbH
  • Leading BioSciences Inc
  • Lotus Pharmaceutical Co Ltd
  • M Pharmaceutical Inc
  • Magnus Life Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Mitochon Pharmaceuticals Inc
  • Mitsubishi Tanabe Pharma Corp
  • NeuroNano Pharma Inc
  • NGM Biopharmaceuticals Inc
  • PharmaIN Corp
  • Poxel SA
  • Progenra Inc
  • Prometheon Pharma LLC
  • ReCyte Therapeutics Inc
  • Renova Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • Saniona AB
  • XL-protein GmbH
  • Yuyu Pharma Inc
  • Zafgen Inc
  • Zealand Pharma AS

For more information about this report visit http://www.researchandmarkets.com/research/t4k8ct/obesity

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Anti-Obesity Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Anti-Obesity Drugs